Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Literature DB >> 24872794

A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Abstract

Entities: Disease Gene Species

Year: 2013 PMID： 24872794 PMCID： PMC4032550

Source DB: PubMed Journal: Gastroenterol Hepatol (N Y) ISSN： 1554-7914

× No keyword cloud information.

20 in total

Review 1. Maximizing the effect of biologics in inflammatory bowel disease.

Authors: R Souto Rodriguez; J M Swoger; M Barreiro-De Acosta; M Regueiro
Journal: Minerva Gastroenterol Dietol Date: 2012-06

2. Age of diagnosis influences serologic responses in children with Crohn's disease: a possible clue to etiology?

Authors: James Markowitz; Subra Kugathasan; Marla Dubinsky; Ling Mei; Wallace Crandall; Neal LeLeiko; Maria Oliva-Hemker; Joel Rosh; Jonathan Evans; David Mack; Anthony Otley; Marian Pfefferkorn; Ron Bahar; Eric Vasiliauskas; Ghassan Wahbeh; Gary Silber; J Antonio Quiros; Iwona Wrobel; Justin Nebel; Carol Landers; Yoanna Picornell; Stephan Targan; Trudy Lerer; Jeffrey Hyams
Journal: Inflamm Bowel Dis Date: 2009-05 Impact factor: 5.325

3. Frequency and predictors of loss of response to infliximab or adalimumab in Crohn's disease after one-year treatment period - a single center experience.

Authors: Tamás Molnár; Klaudia Farkas; Tibor Nyári; Zoltán Szepes; Ferenc Nagy; Tibor Wittmann
Journal: J Gastrointestin Liver Dis Date: 2012-09 Impact factor: 2.008

Review 4. Review article: Causative factors and the clinical management of patients with Crohn's disease who lose response to anti-TNF-α therapy.

Authors: S Danese; G Fiorino; W Reinisch
Journal: Aliment Pharmacol Ther Date: 2011-05-03 Impact factor: 8.171

Review 5. Risk of post-operative complications associated with anti-TNF therapy in inflammatory bowel disease.

Authors: Tauseef Ali; Laura Yun; David T Rubin
Journal: World J Gastroenterol Date: 2012-01-21 Impact factor: 5.742

6. Challenges in pediatric inflammatory bowel disease.

Authors: Athos Bousvaros; Francisco Sylvester; Subra Kugathasan; Eva Szigethy; Claudio Fiocchi; Richard Colletti; Anthony Otley; Devendra Amre; George Ferry; Steven J Czinn; Judy B Splawski; Maria Oliva-Hemker; Jeffrey S Hyams; William A Faubion; Barbara S Kirschner; Marla C Dubinsky
Journal: Inflamm Bowel Dis Date: 2006-09 Impact factor: 5.325

7. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors: Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal: Lancet Date: 2002-05-04 Impact factor: 79.321

8. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial.

Authors: W J Sandborn; S B Hanauer; P Rutgeerts; R N Fedorak; M Lukas; D G MacIntosh; R Panaccione; D Wolf; J D Kent; B Bittle; J Li; P F Pollack
Journal: Gut Date: 2007-02-13 Impact factor: 23.059

9. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial.

Authors: Stephen B Hanauer; William J Sandborn; Paul Rutgeerts; Richard N Fedorak; Milan Lukas; Donald MacIntosh; Remo Panaccione; Douglas Wolf; Paul Pollack
Journal: Gastroenterology Date: 2006-02 Impact factor: 22.682

10. Combined serological, genetic, and inflammatory markers differentiate non-IBD, Crohn's disease, and ulcerative colitis patients.

Authors: Scott Plevy; Mark S Silverberg; Steve Lockton; Tom Stockfisch; Lisa Croner; Jordan Stachelski; Michelle Brown; Cheryl Triggs; Emil Chuang; Fred Princen; Sharat Singh
Journal: Inflamm Bowel Dis Date: 2013-05 Impact factor: 5.325

19 in total

Review 1. Optimizing the use of anti-tumor necrosis factor in the management of patients with Crohn's disease.

Authors: Douglas L Nguyen; Sarah Flores; Kareem Sassi; Matthew L Bechtold; Emily T Nguyen; Nimisha K Parekh
Journal: Ther Adv Chronic Dis Date: 2015-05 Impact factor: 5.091

2. Response to Bodini et al.

Authors: S Paul; X Roblin
Journal: Am J Gastroenterol Date: 2015-03 Impact factor: 10.864

3. A Personalized Approach to Managing Inflammatory Bowel Disease.

Authors: Michael J Kingsley; Maria T Abreu
Journal: Gastroenterol Hepatol (N Y) Date: 2016-05

4. A SPECIAL MEETING REVIEW EDITION: Clinical Research Highlights in IBD: Diagnosis and Anti-Tumor Necrosis Factor Monitoring: Digestive Disease Week 2013May 18-21, 2013 • Orlando, FloridaSpecial Reporting on:• Serological and Inflammatory IBD Marker Prevalence As Function of Age in a Large Cohort of Patients Presenting IBD-Like Gastrointestinal Symptoms• Prevalence of Antibodies to Adalimumab (ATA) and Correlation Between ATA and Low Serum Drug Concentration on CRP and Clinical Symptoms in a Prospective Sample of IBD Patients• Serum Adalimumab Levels and Antibodies Correlate with Endoscopic Intestinal Inflammation and Inflammatory Markers in Patients with Inflammatory Bowel Disease• Comparison of Early Measurement of Infliximab and Antibodies-to-Infliximab Serum Levels with Standard Trough Analysis• Trough Levels and Antidrug Antibodies Predict Safety and Success of Restarting Infliximab After a Long Drug Holiday• A Multi-Center Observational Study in Community Gastroenterology Practices Evaluating the Clinical Usage of Testing for Serum Levels of Infliximab and Antibodies to Infliximab• Preoperative Serum Biologic Levels Do Not Impact Postoperative Outcomes in Ulcerative Colitis• Higher Preoperative Serum Biologic Levels Are Associated with Postoperative Complications in Crohn's Disease PatientsWith Expert Commentary by: William J. Sandborn, MDProfessor and Chief, Division of GastroenterologyDirector, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors:
Journal: Gastroenterol Hepatol (N Y) Date: 2013-08

5. Therapeutic Drug Monitoring of TNF Antagonists in Inflammatory Bowel Disease.

Authors: Reena Khanna; Barrett G Levesque; William J Sandborn; Brian G Feagan
Journal: Gastroenterol Hepatol (N Y) Date: 2014-08

6. A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting: Digestive Disease Week 2014 May 3-6, 2014 • Chicago, Illinois: Special Reporting on:• Therapeutic Monitoring of Anti-TNF Levels and Antibodies to Predict Response and Achieve Mucosal Healing• Prospective Therapeutic Drug Monitoring and Optimization of Infliximab Maintenance Therapy in IBD• Classification of Non-IBD, Crohn's Disease and Ulcerative Colitis in a Young Patient Population Using a Multi-Marker Diagnostic Panel• Persistence of Antibodies to Infliximab for More Than Two Months Predicts Loss of Response to Infliximab in Inflammatory Bowel Diseases• Pre-Operative Serological Markers May Predict Postoperative Crohn's Disease Recurrence: Results From a Prospective Mono-Centric Trial• Antibodies and Levels of Biologies-Reactive vs Proactive Measurements• Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy• The Clinical and Immunological Significance of Low Levels of Infliximab in the Absence of Anti-lnfliximab Antibodies in Patients With IBD• Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy• ATG16L1 Genotype Is Associated With Response to Anti-TNFWith Expert Commentary by:William J. Sandborn, MDProfessor and Chief, Division of Gastroenterology Director, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors:
Journal: Gastroenterol Hepatol (N Y) Date: 2014-07